Program
Tenofovir
Also written as “Tenofovir disoproxil fumarate”, “Tenofovir DF” and “tenofovir”.
Its studies are mostly in Hepatitis B, Chronic · HIV Infections · Hepatitis B · Acquired Immunodeficiency Syndrome · Hepatitis C, led by 12 companies.
Drug pageTenofovir: every studyMany companies study it; this page follows only the 53 they lead. All 291 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 291 open or running | phase 4since Mar 23, 2005 | Nov 2, 1999 | none ahead |
| GlaxoSmithKlineits history only | 90 open or running | phase 4since May 31, 2002 | May 31, 2002 | none ahead |
| Hoffmann-La Rocheits history only | 30 open or running | phase 3since Mar 16, 2010 | Aug 19, 2009 | none ahead |
| Laboratorio Elea Phoenixits history only | 20 open or running | phase 4since Oct 10, 2017 | Oct 19, 2015 | none ahead |
| Novartisits history only | 20 open or running | phase 4since Dec 7, 2006 | Dec 7, 2006 | none ahead |
| Samjin Pharmaceuticalits history only | 20 open or running | phase 4since Feb 25, 2022 | Feb 25, 2022 | none ahead |
| Boryung Pharmaceuticalits history only | 10 open or running | phase 1since Sep 29, 2016 | Sep 29, 2016 | none ahead |
| Daewoong Pharmaceuticalits history only | 10 open or running | phase 4since Mar 27, 2018 | Mar 27, 2018 | none ahead |
| Dong-A STits history only | 10 open or running | phase 1since Sep 22, 2015 | Sep 22, 2015 | none ahead |
| New Discoveryits history only | 10 open or running | phase 4since Mar 18, 2018 | Mar 18, 2018 | none ahead |
| Viatris | 10 open or running | phase 4since Apr 25, 2022 | Apr 25, 2022 | none ahead |
| Yung Shin Pharm. Ind.its history only | 10 open or running | phase 4since Dec 15, 2020 | Dec 15, 2020 | none ahead |
Also a collaborator on its studies: C&R Research, Almedis and Bristol-Myers Squibb.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Viatris only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2016Named tenofovirINNProposed as its International Nonproprietary Name in WHO's List 115
- Apr 25, 2022First study: phase 4 study in Hepatitis B, ChronicFirst studyNCT05355467 · 40 enrolled · Taiwan
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The one study Viatris leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05355467Hepatitis B, Chronic · Taiwan | 4 | Completed | Jul 13, 2021 | 40 |
How it is read
Names in the registry
- “Tenofovir disoproxil fumarate”, 13 entries
- “Tenofovir”, 7 entries
- “Tenofovir DF”, 6 entries
- “tenofovir”, 5 entries
- “TDF”, 4 entries
Conditions, from the studies’ own filings
- Hepatitis B, Chronic, 29 studies
- HIV Infections, 23 studies
- Hepatitis B, 6 studies
- Acquired Immunodeficiency Syndrome, 4 studies
- Hepatitis C, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.